Introduction to the main mechanism of action and therapeutic effects of Erdafitinib

Erdafitinib is an oral targeted drug mainly used to treat patients with urothelial cancer who carry FGFR (fibroblast growth factor receptor) gene mutations or fusions. Its mechanism of action focuses on inhibiting the tyrosine kinase activity of the FGFR family. The FGFR signaling pathway plays an important role in cell proliferation, differentiation and angiogenesis, and the abnormal activation of the FGFR gene is closely related to the occurrence and development of various tumors. By inhibiting FGFRtyrosine kinase, erdafitinib can block abnormal signaling and inhibit the proliferation and survival of tumor cells.

In terms of clinical application, erdafitinib is mainly targeted at patients with locally advanced or metastatic urothelial carcinoma, especially those carrying FGFR2 or FGFR3 gene mutations. Multiple clinical trials have shown that erdafitinib can significantly delay disease progression and improve patients' progression-free survival (PFS) and overall response rate (ORR). Therefore, erdafitinib provides a new targeted treatment option for these patients, which is of great significance, especially for patients with limited efficacy of standard chemotherapy.

The therapeutic effect of erdafitinib is not only reflected in tumor control, but also improves patients' quality of life. Compared with traditional chemotherapy, the side effects of erdafitinib's targeted therapy are relatively controllable. Common adverse reactions include stomatitis, hand-foot syndrome, hyperphosphatemia, etc., but most patients can tolerate it and can be managed by adjusting the dose. In addition, for side effects such as hyperphosphatemia, doctors usually conduct regular monitoring and corresponding symptomatic treatment to ensure the continuity and safety of treatment.

In summary, erdafitinib significantly improves the treatment prospects for patients with urothelial cancer carrying related gene mutations by specifically inhibiting the FGFR pathway. As a first- or second-line targeted drug, the application of erdafitinib has broadened the treatment options for advanced urothelial cancer and provided an important basis for personalized precision treatment. As more research is conducted, the indications and clinical application scope of erdafitinib are expected to be further expanded, benefiting more patients.

Reference link:https://www.balversa.com/